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Abstract 
In this paper, a study exploring the stability of omeprazole in pediatric suspensions is 
presented. In order to determine the most suitable suspension, three different formulations were 
prepared and stored under refrigerated conditions and at room temperature for 30 days. Contents 
of omeprazole and preservatives were determined by liquid chromatographic method. Obtained 
results demonstrate that the vehicle consisting of: xanthan gum 0.3%, sodium bicarbonate 8%, 
Compound hydroxybenzoate solution APF 1% and purified water to 100% could have a 
significant potential in the development of a suitable omeprazole oral liquid for pediatric use. 
Namely, the content of omeprazole in the suspension prepared with this vehicle remained within 
acceptable range during the 30-day period, when stored refrigerated (2–8 °C). 
 






Omeprazole (Figure 1) is a proton pump inhibitor (PPI) commonly prescribed in 
pediatric and neonate population. These patients require oral medications to be given in 
the liquid form and, as can be seen in Table I, there is no such product available 
commercially. For that reason, omeprazole oral liquid products are commonly prepared 
extemporaneously. Stability of omeprazole in commercial vehicles, such as SyrSpend 
SF Alka, has been previously confirmed [1], however, the use of such vehicles is 
frequently limited by their cost and problematic availability on the market of Republic 
of Serbia. Zegerid® powder for oral suspension is marketed in USA and, although it is 
intended that the product is reconstituted immediately before use, the omeprazole 
suspensions prepared in such a way have also demonstrated satisfactory stability [2], but 
this product is also unavailable on the local market. 
 
 
Figure 1.  Structure of omeprazole 
Slika 1.  Struktura omeprazola 
 
Therefore, this study was designed to determine the physical and chemical 
stability of three omeprazole 2mg/mL oral suspension formulations, prepared from 
commercially available omeprazole capsules, low cost and easily available excipients, 
and to identify the most suitable candidate for further studies and its possible inclusion 










Table I   Omeprazole drugs for oral administration marketed in Serbia*. 
Tabela I Lekovi omeprazola za oralnu upotrebu, koji imaju dozvolu/„registrovani” u Srbiji 
 





Dosage form Packaging 
Loseprazol® PRO. MED. CS PRAHA A.S. 20 
gastro-resistant 





20 gastro-resistant capsules, hard blister, 2 x 7 pcs. 
Omeprazol REMEDICA LTD 20 gastro-resistant capsules, hard blister, 2 x 7 pcs. 
Omeprazol HEMOFARM AD VRŠAC 20 
gastro-resistant 
capsules, hard blister, 2 x 7 pcs. 





bottle, 1 x 15 
pcs. 
Omeprol® ZDRAVLJE AD LESKOVAC 20 
gastro-resistant 






10 gastro-resistant capsules, hard 
plastic (HDPE)  







20 gastro-resistant capsules, hard 
plastic (HDPE)  







20 gastro-resistant capsules, hard 
plastic (HDPE) 
bottle, 1 x 14 
pcs. 
* The only omeprazol drug for non-oral administration marketed in Serbia is 
Omeprol®, powder for solution for infusion 








All the reagents utilized in this study were of the analytical grade. The mobile 
phase and the solvents were prepared from acetonitrile (Avantor Performance Materials 
BV, Deventer, Netherlands), potassium hydrogen phosphate (Riedel-de Haën, Sigma-
Aldrich Laborchemikalien GmbH, Seelze, Germany), sodium hydroxide (Riedel-de 
Haën, Sigma-Aldrich Laborchemikalien GmbH, Seelze, Germany) and HPLC grade 
water. 
The analyzed substances omeprazole, methyl p-hydroxybenzoate (MP) and propyl 
p-hydroxybenzoate (PP) were of analytical grade. 
Standard solutions 
Standard solutions of omeprazole for calibration curve were prepared in mobile 
phase. Five solutions in concentration range from 0.025 mg mL-1 to 0.150 mg mL-1 
were prepared.  
Standard solutions of MP and PP for calibration curves were prepared in mobile 
phase. Five solutions in concentration range from 0.0125 mg mL-1 to 0.0750 mg mL-1 
and from 0.0625 mg mL-1 to 0.375 mg mL-1 were prepared for MP and PP, respectively.  
Suspension samples preparation  
All the formulations were prepared in concentration of 2 mg mL-1 omeprazole 
content, which is most commonly prescribed. The samples were prepared with the 
commercially available omeprazole capsules as a source of active ingredient. The 

















Table II  Composition of investigated samples  
Tabela II  Sastav ispitivanih formulacija 
 
Composition Sample label F1 F2 F3 
Omeprazole capsules 
equivalent to 200 mg 
omeprazole 
200 mg 200 mg 200 mg 
Glycerol 85% 15 g - - 
Carmellose sodium 5% gel 15 g - - 
Simple syrup 35 g - - 
Methyl p-hydroxybenzoate 100 mg - - 
Propyl p-hydroxybenzoate 50 mg - - 




- 1 mL 1 mL 
Xanthan gum (USP-NF) - - 300 mg 
Purified water q. s. 100 mL q. s. 100 mL q. s. 100 mL 
*Methyl hydroxybenzoate 8% and Propyl hydroxybenzoate 2% in Propylene glycol 
F1 formulation is frequently prepared in local pharmacies. The contents of 
omeprazole capsules (enteric-coated pellets) were pulverized, with (F1*) and without 
pre-treatment with ethanol (F1). Some centers report pre-treatment of omeprazole 
pellets with 5 mL of Ethanol 96% as a processing aid [3].  
Formulation F2 presents Australian pharmaceutical formulary and handbook 22nd 
edition (APF22) officinal Omeprazole dispersion [4].  
Formulation F3 is a modification of the APF22 formula: Xanthan gum USP-NF 
0.3% was added as a rheology modifier, in order to improve the physical properties of 
the suspension. The choice of excipients in this formulation was based on previously 
reported chemically stable suspension formulation, with proven record of efficacy 
(simple omeprazole dispersion in sodium bicarbonate solution, as recorded in APF22), 
while attempting to improve its physical properties by increasing viscosity and thus 




based on its long history of safe use in oral medications, as well as the stability study of 
the reconstituted Zegerid®  powder, which contains this excipient. A conscious effort 
was made to develop simple and affordable formulation, allowing for straightforward 
preparation from readily available ingredients. 
The following procedure is recommended for preparation of this suspension: 
1. Place in a suitable vessel approximately 85% of the final volume (85 ml for 
each 100 ml of suspension) of freshly boiled and cooled purified water. Place 
this on a magnetic stirrer and mix on sufficiently high speed to form a stable 
vortex. 
2. Sift the xanthan gum into the vortex and continue mixing on a high speed, in a 
covered vessel, until gum is completely hydrated. The resulting mucilage is 
opalescent and free from undispersed agglomerates.  
3. Add compound hydroxybenzoate solution to the mucilage and continue 
mixing until homogenous.  
4. Add sodium bicarbonate and continue mixing until completely dissolved. 
5. Empty the contents of omeprazole capsules into a porcelain mortar. Carefully 
pulverise the granules, avoiding any losses. 
6. Levigate the resulting powder with small portion of the mucilage. Mix in 
approximately half of the remaining mucilage, in portions, mixing well after 
each addition. Transfer this into the measuring cylinder. 
7. Rinse the mortar with remaining mucilage, in portions, and add these to the 
measure. 
8. Rinse the mucilage vessel and the mortar with few small aliquots of purified 
water. Add these to the measure. 
9. Make up to final volume with purified water. Mix until homogenous, bottle 
and label as required. 
The investigation of stability  
Stability of the samples was studied in regards to storage temperature (refrigerated 
and room temperature), packaging (amber glass), and pre-treatment of omeprazole 
pellets (pellets pulverized with and without pre-treatment with ethanol). The samples 
have been evaluated visually for homogeneity and appearance, the pH values measured 
(potentiometric method), and the contents of omeprazole determined, immediately after 





The chromatographic system Waters Breeze (USA) consisted of Waters 1525 
Binary HPLC Pump, Waters 2487 UV/VIS dual absorbance detector and Breeze 
Software Windows XP for data collection. Separations were performed on the Zorbax 
Eclipse XDBC18 4.6 mm x 150 mm, 5 m particle size column (Agilent 
Technologies, USA). UV detection was performed at 280 nm. The samples were 
introduced through a Rheodyne injector (USA) valve with a 20 L sample loop. Mobile 
phase consisted of 32% acetonitrile and 68% aqueous solution. Aqueous solution 
contains 50 mM potassium hydrogen phosphate and pH value of this solution was 
adjusted to 7.0 with 1 M solution of sodium hydroxide.  Flow rate was 1 mL min-1 and 
column temperature was 25 °C. UV detection was carried out at 280 nm.  
Results and discussion 
In the beginning of the study, some important characteristics of omeprazole were 
realized. Omeprazole has two pKa values (4.0 and 8.7 originate from pyridinium and 
benzimidazole, respectively). In respect  to solubility, it is very slightly soluble in water, 
soluble in methylene chloride, sparingly soluble in ethanol and in methanol [5]. It 
dissolves in dilute solutions of alkali hydroxide. 
PPIs are the most effective medications used in treatment of gastroesophageal 
reflux disease (GERD). Omeprazole is commonly prescribed to infants and children 
with GERD, and alongside its enantiomer esomeprazole, is the only PPI approved for 
use in pediatrics in Europe [6]. As it was shown in Table I, on the market of Republic of 
Serbia, omeprazole for oral use is available solely in the form of hard gelatin capsules 
filled with gastro-resistant pellets, in 10 mg and 20 mg doses [7]. The capsules are 
intended to be swallowed whole, although in practice it has been reported that the 
capsules may be opened and the contents mixed with suitable liquid or soft non-alkaline 
food (e.g., fruit juice, apple puree and fruit yoghurt) immediately before administration. 
Caution must be taken that the pellets are not crushed or chewed on, in order to preserve 
their enteric coating. This administration method may be suitable for people with 
swallowing difficulties and children, but it is not adequate for administration via feeding 
tubes (pellets tend to block the tubes) and toddlers (chewing on pellets, fraction of dose 
required). For use in this group of patients, omeprazole has to be extemporaneously 
prepared in the form of oral suspension. Bioavailability of such suspensions is lower in 
comparison to enteric-coated products, due to rapid degradation of omeprazole in acidic 
pH (stomach). In order to improve bioavailability, and reduce the degradation of 
omeprazole, oral suspensions are commonly prepared with the addition of an antacid 
(sodium bicarbonate or calcium carbonate), where the temporary rise in pH of stomach 
content is thought to protect the omeprazole from degradation [8,9]. This approach is 




oral suspension; neither of which is enteric coated, but rather they both contain sodium 
bicarbonate.  Packets of powder for oral suspension contain either 40 mg or 20 mg of 
omeprazole, 1680 mg of sodium bicarbonate, and the following excipients: xylitol, 
sucrose, sucralose, xanthan gum, and flavorings [10]. Omeprazole is highly unstable in 
acidic conditions (pH<7.8) [11] and as such it is not compatible with acidic excipients 
commonly used in preparation of oral liquids (for example Vehicle for oral suspension 
USP40-NF35 and Vehicle for oral solution USP40-NF35, which are buffered to pH 4.0-
5.0) [12]. Under these conditions, omeprazole is only very slightly soluble and most of 
it will be suspended in the vehicle, necessitating the addition of suitable suspending 
agents or rheology modifiers/thickeners, in order to allow precise dosing. These 
products are commonly preserved with parabens, which are antimicrobially active at pH 
8, although non-preserved formulations have been reported. 
In order to determine content of omeprazole in the formulations liquid 
chromatographic (LC) method was used. Literature survey shown that LC method 
presents the most often used method for its determination in different samples [13-15]. 
In this study, aim of chromatographic analysis was adequate separation between 
omeprazole and preservatives (MP and PP). Desired characteristics of chromatographic 
analysis were achieved under chromatographic conditions described in Experimental 
part. Obtained results for calibration curves are presented in Table III. 
 
Table III  Parameters of calibration curves for omeprazole, methyl p-hydroxybenzoate and 
propyl p-hydroxybenzoate 
Tabela III Parametri kalibracionih krivih za omeprazol, metil-p-hidroksibenzoat i propil-p- 
                    hidroksibenzoat 
 
Substance Coefficient of correlation 
Intercept 
(b) 




Omeprazole 0.9994 68.35391 0.224 30.415 
MP* 0.9992 -124.195 0.0243 35.770 
PP** 0.9985 -22.1995 0.290 31.128 
 
MP* – Methyl p-hydroxybenzoate 
PP** – Propyl p-hydroxybenzoate 
 
On the basis of calibration curves contents of omeprazole, MP and PP were 




IV, while concentrations of MP and PP were in range from 90% from 110% in all 
investigated points. 
 
Table IV  Results for Omeprazole determination in different formulations (stored in amber 
glass bottles, refrigerated at 2-8 C or kept at room temperature) 
Tabela IV  Rezultati određivanja sadržaja omeprazola u ispitivanim formulacijama (čuvanim u  





Content of omeprazole (%) 
after 24 h after 7 days after 30 days 
F1 2-8 C 7.72 88.3 84.9 81.0 
F1 20-25°C 7.72 83.5 72.3 61 
F1* 2-8 C 7.52 82.8 77.1 73.0 
F1* 20-25°C 7.52 77.6 68 35 
F2 2-8 C 8.59 98.5 93.3 100.0 
F3 2-8 C 8.05 95.1 97.4 101.3 
 
*content of omeprazole capsules pretreated with ethanol 
Since  GERD is a chronic disorder that usually requires long term therapy, the 
product with a demonstrated stability of at least one month was considered suitable 
since, medications for chronic disorders are usually dispensed in monthly intervals. A 
30-days long stability study was performed as an initial assessment of feasibility of the 
extemporaneous preparation of such a product, with the requirement that product retains 
minimum 95% of the declared concentration of omeprazole, when kept under defined 
storage conditions. 
Obtained results (Table IV) favor mechanical pulverization of pellets or their 
dispersion in an alkaline medium (pulverization of pellets pretreated with ethanol has 
resulted in suspensions with significantly reduced omeprazole contents), as well as 
refrigerated storage. Samples F2 and F3 retained more than 95% of initial omeprazole 
contents when stored refrigerated (2-8 °C) over the 30-day period. These findings 
correspond with the literature data regarding chemical stability of simple omeprazole 
dispersions with sodium bicarbonate [2,16]. APF22 officinal Omeprazole dispersion 
(sample F2) was proven to be difficult to prepare since the pellets took many hours 
(overnight) to fully disintegrate in the sodium bicarbonate solution. Also, due to the 
absence of any rheology modifiers, this product shows high rate of sedimentation and 
the sediment is prone to caking, both of these factors likely affecting the precision of 




containing xanthan gum, sodium bicarbonate and parabens, has demonstrated better 
physical properties in comparison to sample F2. Xanthan gum was added into sample 
F3 as a suspending and stabilizing agent, in order to obtain homogenous suspension that 
can be easily resuspended.  
Storage at controlled room temperature of sample F1 resulted in significant 
omeprazole losses: only 35–61% of the declared omeprazole content retained after 30 
days. Representative chromatogram of one formulation is presented in Figure 2. 
 
Figure 2. Chromatogram of sample F1: methyl p-hydroxybenzoate 3.932 min., omeprazole  
 4.474 min. and propyl p-hydroxybenzoate 12.866 min. 
Slika 2.  Hromatogram uzorka F1: metil-p-hidroksibenzoat 3,932 min.,  
 omeprazol 4,474 min i propil-p-hidroksibenzoat 12,866 min. 
Conclusion 
The findings of this study  demonstrate that an extemporaneously compounded 
vehicle consisting of: xanthan gum 0.3%, sodium bicarbonate 8%, Compound 
hydroxybenzoate solution APF 1% and purified water to 100% is an adequate 
suspending vehicle for preparing individually compounded omeprazole oral liquid 
formulations. This formulation can be considered stable for 30 days when stored in an 
amber glass bottle, refrigerated at 2-8 oC and therefore, has significant potential as 
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Kratak sadržaj 
U ovom radu predstavljeno je ispitivanje stabilnosti omeprazola u suspenzijama za 
pedijatrijsku primenu, koje su izrađene iz komercijalno dostupnih kapsula omeprazola u 
uslovima apoteke. U cilju utvrđivanja najpogodnijeg vehikuluma za magistralnu izradu 
suspenzija omeprazola, pripremljene su tri formulacije, koje su potom 30 dana čuvane u 
frižideru i na sobnoj temperaturi. Sadržaj omeprazola i konzervansa u suspenzijama je 
određivan primenom tečne hromatografije. Dobijeni rezultati ukazuju da vehikulum koji se 
sastoji iz ksantan gume 0,3%, natrijum-bikarbonata 8%, rastvora parabena 1% (Compound 
hydroxybenzoate solution APF) i prečišćene vode do 100% ima značajan potencijal za razvoj 
pogodnog tečnog oblika omeprazola za peroralnu primenu u pedijatrijskoj populaciji. Naime, 
sadržaj omeprazola u suspenziji pripremljenoj primenom ovog vehikuluma je ostao u okviru 
prihvatljivih granica tokom perioda od 30 dana, kada je suspenzija čuvana u frižideru (2-8oC). 
 
Ključne reči:  omeprazol, stabilnost, suspenzija za pedijatrijsku primenu,  
tečna hromatografija 
 
